Efficiency metrics are useful in medicinal chemistry to track small molecule progress in lead optimization (LO). Molecular glue degraders are small molecules that mediate targeted protein degradation ...

Efficiency metrics are useful in medicinal chemistry to track small molecule progress in lead optimization (LO). Molecular glue degraders are small molecules that mediate targeted protein degradation ...

Bristol Myers Squibb’s Zenbexus is the first FDA-approved drug in a new class of cancer drugs called CELMoDs. The pharma company is positioning this molecule as a successor to its legacy products for ...

Joshua Richter, MD, discusses the use of next-generation CELMoDs to boost T-cell responses with bispecific antibodies or CAR T-cell therapy in myeloma.

The roundtable panelists discuss where CELMoDs, including mezigdomide and iberdomide, fit in the multiple myeloma treatment landscape. The panel evaluates the distinct toxicity profiles of these…

Key PointsCRBN missense mutations identified in patients were modeled to explore their effect on CRBN function with IMiD and CELMoD therapy.Mutations led t

Efficiency metrics are useful in medicinal chemistry to track small molecule progress in lead optimization (LO). Molecular glue degraders are small molecules that mediate targeted protein degradation ...

Exploring CAR T-cell therapy, BiTE therapy, CELMoDs and more

Cereblon E3 ligase modulatory drugs (CELMoDs) can be used to target proteins and mark them for proteasomal degradation by recruiting them to cereblon (CRBN), the substrate receptor of the CRL4CRBN E3 ...

Glutarimide-containing Cereblon (CRBN) ligands are critical motifs for PROTACs, molecular glue degraders and next-generation Cereblon E3 ligase modulatory drugs (CELMoDs), which represent promising therapeutic modalities in targeted protein degradation. However, the multistep synthetic routes required to access glutarimide scaffolds continue to present formidable challenges for medicinal chemists, limiting rapid structure–activity relationship (SAR) exploration and late-stage diversification. To streamline access to these privileged motifs, modular and efficient methodologies are still highly desirable. Here, we report a unified organocatalytic synthesis platform for the rapid assembly of diverse glutarimide derivatives from readily available nitrogen heterocycles. Employing a sequence of phosphine-catalysed C–N bond formation, metal-free Giese addition and acid-mediated cyclisation, this approach provides high selectivity, broad functional group tolerance and operational simplicity un

The first- and second-generation immunomodulatory drugs (IMiDs) have fundamentally transformed the treatment landscape of multiple myeloma (MM) over the past two decades. Lenalidomide combinations…

Read the full paper: Cellular and molecular impacts of <fc>CELMoDs</fc> and <fc>IMiD</fc> on the induction of myeloid‐derived suppressor cells by myeloma cells

Explore the Hematology Strategic Roundup covering July 13–August 14, 2026, and how multiple myeloma platform competition is accelerating across CELMoDs, bispecific antibodies, and precision approaches. The roundup examines major strategic themes from the reporting period, including treatment sequencing, earlier-line expansion, mechanism-driven innovation, and evidence generation. Watch the full Strategic Roundup for deeper strategic analysis.

Bristol Myers Squibb’s Zenbexus is the first FDA-approved drug in a new class of cancer drugs called CELMoDs. The pharma company is positioning this molecule as a successor to its legacy products for multiple myeloma. The post Bristol Myers Squibb Protein Degrader Wins First-in-Class FDA Nod in Multiple Myeloma appeared first on MedCity News .

The promise of CELMoDs in myeloma treatment is discussed in this final video of the roundtable series on the topic.

EHA 2026 panel discusses combining trispecifics and CELMods for patients with relapsed or refractory multiple myeloma.

EHA 2026 roundtable panel discusses combining CELMoDs with CAR T-cell therapies and ADCs for relapsed or refractory multiple myeloma.

YouTube video by SOHO Insider